Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer

Gastric Cancer

Volumn 8, Issue 1, 2005, Pages 18-28

  Wang, Liwei ^a   Shi, Gary G ^a   Yao, James C ^a   Gong, Weida ^a   Wei, Daoyan ^a   Wu, Tsung Teh ^a   Ajani, Jaffer A ^a   Huang, Suyun ^a   Xie, Keping ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Metastasis; Prognosis; Transcription factor Sp1; Tumor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR SP1;

ADULT; AGE; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME ASSAY; EVALUATION; FEMALE; GASTRECTOMY; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA;

AGE FACTORS; AGED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SP1 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS;

EID: 15444372807     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-004-0310-7     Document Type: Article

References (61)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84: 9265-9.
2. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-42.
3. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003;284:R1-12.
4. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002;7:149-64.
5. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann NY Acad Sci 2002;962:122-30.
6. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002;64:749-74.
7. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol 1998;152: 1667-79.
8. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 1998;17:91-106.
9. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002;90:966-73.
10. Ma L, Chow JY, Cho CH. Cigarette smoking delays ulcer healing: role of constitutive nitric oxide synthase in rat stomach. Am J Physiol 1999;276:0238-48.
11. Brzozowski T, Konturek SJ, Drozdowicz D, Dembinski A, Stachura J. Healing of chronic gastric ulcerations by L-arginine. Role of nitric oxide, prostaglandins, gastrin and polyandries. Digestion 1995;56:463-71.
12. Soini Y, Puhakka A, Kahlos K, Saily M, Paakko P, Koistinen P, et al. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology 2001; 39:179-86.
13. Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999;41:773-80.
14. Chinje EC, Stratford IJ. Role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 1997;32:61-72.
15. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 2003;34: 969-86.
16. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85.
17. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000;86:30-9.
18. Martin JH, Begum S, Alalami O, Harrison A, Scott KW. Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 2000;21:90-7.
19. Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U, Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 1999;54: 416-9.
20. Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 1997;57:1233-7.
21. Chhatwal VJ, Ngoi SS, Chan ST, Chia YW, Moochhala SM. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonie mucosa and surrounding peritumoral normal mucosa. Carcinogenesis 1994;15:2081-5.
22. Iwata S, Nakagawa K, Harada H, Oka Y, Kumon Y, Sakaki S. Endothelial nitric oxide synthase expression in tumor vasculature is correlated with malignancy in human supratentorial astrocytic tumors. Neurosurgery 1999;45:24-8.
23. Nussler AK, Gansauge S, Gansauge F, Fischer U, Butzer U, Kremsner PG, et al. Overexpression of endothelium-derived nitric oxide synthase isoform 3 in the vasculature of human pancreatic tumor biopsies. Langenbecks Arch Surg 1998;383:474-80.
24. Koh E, Noh SH, Lee YD, Lee HY, Han JW, Lee HW, et al. Differential expression of nitric oxide synthase in human stomach cancer. Cancer Lett 1999;146:173-80.
25. Doi C, Noguchi Y, Marat D, Saito A, Fukuzawa K, Yoshikawa T, et al. Expression of nitric oxide synthase in gastric cancer. Cancer Lett 1999;144:161-7.
26. 2+-dependent nitric oxide synthase activity in human astrocytoma cells. J Biol Chem 1997;272:7582-5.
27. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998;17:7-23.
28. Wariishi S, Miyahara K, Toda K, Ogoshi S, Doi Y, Ohnishi S, et al. A SP1 binding site in the GC-rich region is essential for a core promoter activity of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun 1995;216:729-35.
29. Tang JL, Zembowicz A, Xu XM, Wu KK. Role of Sp1 in transcriptional activation of human nitric oxide synthase type III gene. Biochem Biophys Res Commun 1995;213:673-80.
30. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 1995;270:15320-6.
31. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;268:17478-88.
32. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
33. Suske G. The Sp-family of transcription factors. Gene 1999;238: 291-300.
34. Abdelrahim M, Samudio I, Smith R 3rd, Burghardt R, Safe S. Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 2002;277:28815-22.
35. Chen F, Zhang F, Rao J, Studzinski GP. Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. Anticancer Res 2000;20:661-7.
36. Kumar AP, Butler AP. Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 1999;137:159-65.
37. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9:6371-80.
38. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001;61:4143-54.
39. Tschugguel W, Schneeberger C, Unfried G, Czerwenka K, Weninger W, Mildner M, et al. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res Treat 1999;56:145-51.
40. Lin Z, Chen S, Ye C, Zhu S. Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res 2003;31:232-5.
41. Shochina M, Fellig Y, Sughayer M, Pizov G, Vitner K, Podeh D, et al. Nitric oxide synthase immunoreactivity in human bladder carcinoma. Mol Pathol 2001;54:248-52.
42. Felley-Bosco E, Bender F, Quest AF. Caveolin-1-mediated post-transcriptional regulation of inducible nitric oxide synthase in human colon carcinoma cells. Biol Res 2002;35:169-76.
43. Broholm H, Rubin I, Kruse A, Braendstrup O, Schmidt K, Skriver EB, et al. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol 2003;22:273-81.
44. Broholm H, Braendstrup O, Lauritzen M. Nitric oxide synthase expression of oligodendrogliomas. Clin Neuropathol 2001;20: 233-8.
45. Rajnakova A, Goh PM, Chan ST, Ngoi SS, Alponat A, Moochhala S. Expression of differential nitric oxide synthase isoforms in human normal gastric mucosa and gastric cancer tissue. Carcinogenesis 1997;18:1841-5.
46. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK. Nitric oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 1999;81:889-96.
47. Liu R, Oberley TD, Oberley LW. Effects of endothelial nitric oxide synthase gene expression on the tumor biology of human oral carcinoma SCC-25 cells. Cell Growth Differ 1998;9:239-46.
48. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
49. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis -correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
50. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-91.
51. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000;153:7-12.
52. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-7.
53. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35.
54. Guo YS, Beauchamp RD, Jin GF, Townsend CM Jr, Thompson JC. Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer cells. Gastroenterology 1993;104:15951-604.
55. Du JR, Jiang Y, Zhang YM, Fu H. Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003;9:1604-6.
56. Takahashi R, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003;64:266-74.
57. Joo YE, Sohn YH, Joo SY, Lee WS, Min SW, Park CH, et al. The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med 2002;17: 211-9.
58. Lu M, Jiang Y, Wang R. The relationship of vascular endothelial growth factor and angiogenesis to the progression of gastric carcinoma. Zhonghua Bing Li Xue Za Zhi (Chin J Pathol) 1998;27:278-81.
59. Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000;15:455-62.
60. Tenderenda M, Rutkowski P, Jesionek-Kupnicka D, Kubiak R. Expression of CD34 in gastric cancer and its correlation with histology, stage, proliferation activity, p53 expression and apoptotic index. Pathol Oncol Res 2001;7:129-34.
61. Chen CN, Cheng YM, Lin MT, Hsieh FJ, Lee PH, Chang KJ. Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg 2002;235:512-8.